Your source for all Prime Therapeutics' January 2026 Drug Insights publications.

Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for December 2025 will keep you informed on what’s trending now and trending clinical topics. 

---

Released Jan. 13, 2026

Watch List

A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are celmidsogene lanparvovec, pariglasgene brecaparvovec and more.

---

Released Jan. 13, 2026

High-Cost Therapy Profile

Providing a clinical deep dive into a select high-cost drug in the pipeline, this month's profile features sasanlimab, a monoclonal antibody used in part to help treat non-muscle invasive bladder cancer.

---

Released Jan. 14, 2026

Oncology Insights

Featuring commentary by Simone Ndujiuba, PharmD, BCOP, on developments in the oncology space, this installment takes a look back at what 2025 revealed about the future of oncology care, offering a comprehensive review on the developments already shaping managed care decision making. 

---

Released Jan. 15, 2026

FDA Decisions Expected: February 2026

A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers idebenone, navepegritide and more.

---

Released Jan. 20, 2026

Cell & Gene Pipeline Outlook: January 2026

Our newest publication tracks what is ahead in the cell and gene therapy (CGT) pipeline over the next few years. Check out our latest edition for insights on cell therapies — including CAR-T — and gene therpies poised for growth. 

---

Released Jan. 21, 2026

Expert Clinical Network Insights: January 2026

Committed to keeping you informed on the latest specialty drug insights from leading experts, this newsletter features insights on the FDA's approval of onasemnogene abeparvovec-brve for the treatment of spinal muscular atrophy (SMA).

---

Released Jan. 22, 2026

Trending Topics & Drug Approvals: January 2026

Prime covers hot topics and the latest specialty and traditional drug approvals. The latest edition features the CDC's updated childhood immunization schedule and the new recommendations from the Advisory Committee on Immunization Practices.

---

Released Jan. 26, 2026

Quarterly Drug Approvals: January 2026 

Prime provides a quarterly drug pipeline report of anticipated new drugs, deep dives and indications for the following pipelines: traditional, specialty drugs, biosimilars, and gene and cell therapy. 

---

Released Jan. 27, 2026

Quartely Drug Pipeline: January 2026

Dive into clinical insights and competitive intelligence on anticipated drugs in development, so you are well-sourced on the drug pipeline. 

---

Looking for previous 2025 drug insights publications?

Simply click on the month to access past editions of our drug insights.

December 2025

November 2025

October 2025

September 2025

August 2025

July 2025

June 2025

May 2025

April 2025

March 2025

February 2025

January 2025